Search research articles
Contact Us
Filters
Showing results (131-140 of 153) with videos related to
Page
of 16
Sort By:
Blood
|
January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial
Marc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.
BMC Cancer
|
April 27, 2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
Marc-Andrea Baertsch, Jana Schlenzka, Elias K Mai, et al.
Leukemia
|
July 23, 2020
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
Hartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, et al.
European Journal of Radiology
|
April 7, 2007
Efficacy and safety of gadodiamide (Gd-DTPA-BMA) in renal 3D-magnetic resonance angiography (MRA): a phase II study
Thomas Kittner, Jens Rudolf, Joan Falco Fages, et al.
Leukemia
|
December 7, 2023
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients
Elias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Cancers
|
September 27, 2025
Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy
Katja Krüger, Razif Gabdoulline, Martin Wichmann, et al.
European Radiology
|
July 9, 2008
Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: results of a multicenter, single-blind, interindividual, randomized clinical phase III trial
Bernd Tombach, Klaus Bohndorf, Wolfgang Brodtrager, et al.
The Lancet. Haematology
|
February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
Elias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 12, 2017
Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
Mohamed A Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, et al.
Leukemia
|
June 3, 2024
CD8<sup>+</sup> CD28<sup>-</sup> regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
Katharina Kriegsmann, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, et al.
Page
of 16
Search research articles
Search
Showing results (131-140 of 153) with videos related to
Sort By:
Page
of 16
Blood
|
January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial
Marc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.
BMC Cancer
|
April 27, 2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
Marc-Andrea Baertsch, Jana Schlenzka, Elias K Mai, et al.
Leukemia
|
July 23, 2020
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
Hartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, et al.
European Journal of Radiology
|
April 7, 2007
Efficacy and safety of gadodiamide (Gd-DTPA-BMA) in renal 3D-magnetic resonance angiography (MRA): a phase II study
Thomas Kittner, Jens Rudolf, Joan Falco Fages, et al.
Leukemia
|
December 7, 2023
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients
Elias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Cancers
|
September 27, 2025
Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy
Katja Krüger, Razif Gabdoulline, Martin Wichmann, et al.
European Radiology
|
July 9, 2008
Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: results of a multicenter, single-blind, interindividual, randomized clinical phase III trial
Bernd Tombach, Klaus Bohndorf, Wolfgang Brodtrager, et al.
The Lancet. Haematology
|
February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
Elias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 12, 2017
Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
Mohamed A Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, et al.
Leukemia
|
June 3, 2024
CD8<sup>+</sup> CD28<sup>-</sup> regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
Katharina Kriegsmann, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, et al.
Page
of 16